RxDoctor Payments Data

Geeta Rode, MD

Pulmonary Disease · Flint, MINPI 1033132188

Payments from drug & device makers

$1,189in general payments, 2019–2025

Across 71 payments — averaging $16.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$430
  • Pulmonx Corporation$143
  • Insmed, Inc.$78
  • AstraZeneca$73
  • Amgen$65
  • Genentech USA, Inc.$55
  • plus $345 from 11 others

What the payments were for

  • Food & beverage$1,189100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,189 in reported general payments places this provider in the 45th percentile of 463 pulmonary disease providers in Michigan.

See all pulmonary disease providers in Michigan

Medicare billing

Part B allowed, 2024
$99,891
Medicare patients
199
Services billed
1,165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter652$515,880
Spiriva RespimatTiotropium Bromide59$52,897
Breo ElliptaFluticasone/Vilanterol60$43,016
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$33,355
Tiotropium Bromide33$30,861
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate60$27,275
SymbicortBudesonide/Formoterol Fumarate78$25,053
Incruse ElliptaUmeclidinium Bromide28$17,550
Albuterol Sulfate HfaAlbuterol Sulfate360$15,050
Fluticasone-SalmeterolFluticasone Propion/Salmeterol52$11,685
Advair HfaFluticasone Propion/Salmeterol19$10,137
Ventolin HfaAlbuterol Sulfate91$9,107
Combivent RespimatIpratropium/Albuterol Sulfate13$8,116
Spiriva HandihalerTiotropium Bromide15$7,893
DuleraMometasone/Formoterol11$6,353

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$430$576,445740 claims
Boehringer IngelheimSpiriva Respimat, Combivent Respimat$43$61,01372 claims
AstraZenecaBreztri Aerosphere, Symbicort$73$58,408105 claims
MerckDulera$39$6,35311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 463 pulmonary disease providers in Michigan.

Other pulmonary disease in Flint

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →